|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 14
Zeitschriftenartikel
Hartlapp, I.; Valta-Seufzer, D.; Siveke, J. T.; Algul, H.; Goekkurt, E.; Siegler, G.; Martens, U. M.; Waldschmidt, D.; Pelzer, U.; Fuchs, M.; Kullmann, F.; Boeck, S.; Ettrich, T. J.; Held, S.; Keller, R.; Anger, F.; Germer, C. T.; Stang, A.; Kimmel, B.; Heinemann, V. und Kunzmann, V.
(2022):
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113).
In: ESMO Open, Bd. 7, Nr. 4
Holch, J. W.; Held, S.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Kaiser, F.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Einem, J. C. von; Michl, M. und Heinemann, V
(2020):
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
In: Annals of Oncology, Bd. 31, Nr. 1: S. 72-78
Stintzing, S.; Wirapati, P.; Lenz, H. J.; Neureiter, D.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Kaiser, F.; Al-Batran, S.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Moehler, M.; Scheithauer, W.; Held, S.; Modest, D. P.; Jung, A.; Kirchner, T.; Aderka, D.; Tejpar, S. und Heinemann, V
(2019):
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
In: Annals of Oncology, Bd. 30, Nr. 11: S. 1796-1803
Holch, J. W.; Ricard, I.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Jelas, I.; Modest, D. P.; Westphalen, C. B.; Einem, J. C. von; Michl, M. und Heinemann, V.
(2018):
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
In: European Journal of Cancer, Bd. 106: S. 115-125
Haas, M.; Siveke, J. T.; Schenk, M.; Lerch, M. M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Kanzler, S.; Kunzmann, V.; Ettrich, T. J.; Kruger, S.; Westphalen, C. B.; Held, S.; Heinemann, V. und Böck, S.
(2018):
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
In: European Journal of Cancer, Bd. 94: S. 95-103
Modest, Dominik P.; Ricard, Ingrid; Stintzing, Sebastian; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Westphalen, C. B.; Holch, Julian W.; Einem, J. C. von; Held, S. und Heinemann, Volker
(2017):
Evaluation of survival across several treatment lines in
metastatic colorectal cancer: analysis of the FIRE-3 trial (AIO KRK0306).
In: European Journal of Cancer, Bd. 84: S. 262-269
Stintzing, S.; Miller-Phillips, L.; Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jagenburg, A.; Kirchner, T.; Jung, A. und Heinemann, V.
(2017):
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
In: European Journal of Cancer, Bd. 79: S. 50-60
Holch, J. W.; Stintzing, S.; Held, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Kirchner, T.; Einem, J. C. von; Modest, D. P. und Heinemann, V.
(2017):
Right-sided colorectal cancer (RC): response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR).
In: Oncology Research and Treatment, Bd. 40: S. 164-165
Haas, M.; Böck, S.; Siveke, J. T.; Schenk, M.; Lerch, M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Ettrich, T. J.; Kanzler, S.; Kunzmann, V.; Kruger, S.; Westphalen, C. B.; Held, S. und Heinemann, V.
(2017):
Efficacy of gemcitabine plus erlotinib for rash-positive metastatic pancreatic cancer patients eligible for treatment with FOLFIRINOX - a prospective phase II trial of the "Arbeitsgemeinschaft Internistische Onkologie" - AIO.
In: Oncology Research and Treatment, Bd. 40: S. 207-208
Michl, M.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Hielscher, J.; Scholz, M.; Mueller, S.; Lerch, M. M.; Modest, D. P.; Kirchner, T.; Jung, A. und Heinemann, V.
(2016):
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro).
In: Annals of Oncology, Bd. 27, Nr. 8: S. 1565-1572
Modest, D. P.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
Clinical relevance of subsequent treatment procedures on overall survival in FIRE-3/AIO KRK0306 (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) in patients with KRAS wild-type metastatic colorectal cancer.
In: Oncology Research and Treatment, Bd. 39: S. 11
Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmueller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Hielscher, J.; Lerch, M.; Scheithauer, W.; Jagenburg, A.; Held, S.; Modest, D.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306).
In: Annals of Oncology, Bd. 27: S. 112
Haas, M.; Heinemann, V.; Kullmann, F.; Laubender, Rüdiger P.; Klose, C.; Bruns, C. J.; Holdenrieder, S.; Modest, D. P.; Schulz, C. und Boeck, S.
(2013):
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
In: Journal of Cancer Research and Clinical Oncology, Bd. 139, Nr. 4: S. 681-689
Boeck, S.; Haas, M.; Laubender, Rüdiger P.; Kullmann, F.; Klose, C.; Bruns, C. J.; Wilkowski, R.; Stieber, P.; Holdenrieder, S.; Buchner, Hannes; Mansmann, Ulrich und Heinemann, V.
(2010):
Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
In: Clinical Cancer Research, Bd. 16, Nr. 3: S. 986-994